

# ISO/TR 22442-4:2010-12 (E)

## Medical devices utilizing animal tissues and their derivatives - Part 4: Principles for elimination and/or inactivation of transmissible spongiform encephalopathy (TSE) agents and validation assays for those processes

---

<b>Contents</b>		<b>Page</b>
Foreword .....		iv
Introduction .....		v
<b>1</b>	<b>Scope .....</b>	<b>1</b>
<b>2</b>	<b>Normative references .....</b>	<b>1</b>
<b>3</b>	<b>Terms and definitions .....</b>	<b>2</b>
<b>4</b>	<b>Elimination of TSE agents: basic considerations .....</b>	<b>2</b>
4.1	General .....	2
4.1.1	TSEs of concern .....	2
4.1.2	Animal tissues of concern .....	2
4.1.3	Tissues infected with TSE agents .....	2
<b>5</b>	<b>Potential methods to eliminate TSE agents .....</b>	<b>3</b>
5.1	Methods for inactivating infectivity .....	3
5.1.1	General .....	3
5.1.2	Physical methods for inactivating TSE infectivity .....	3
5.1.3	Chemical methods for inactivating TSE infectivity .....	4
5.2	Methods for removing TSE infectivity without inactivating infectivity .....	5
<b>6</b>	<b>Experimental validation of methods for eliminating TSE agents from medical devices utilizing non-viable animal tissues .....</b>	<b>6</b>
6.1	General .....	6
6.2	Defining of product families for purposes of designing TSE process validation studies .....	6
6.3	Selection and testing of product for establishing and verifying the infecting dose of TSE agent .....	6
6.4	TSE agent spiking materials .....	6
6.5	Availability of bioassay animals (conventional and transgenic mice, other rodents, farm animals) .....	7
6.6	Potential development of cell culture assays for infectivity .....	7
6.7	Correlations between PrPTSE and infectivity assays .....	7
6.8	Reductions in infectivity compared with failure to detect at limits of detection .....	8
6.9	Determining numbers of replicate validations needed to support inferences of reduction in infectivity rather than variations in assay performance .....	8
6.10	Requirements for step-wise reductions in PrPTSE and infectivity verses whole-process validation .....	8
Bibliography .....		9